Silo Pharma, Inc. (SILO) Financial Statements (2026 and earlier)

Company Profile

Business Address 677 N. WASHINGTON BLVD
SARASOTA, FL 34236
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6,8597,0817,66511,3679,8371,128
Cash and cash equivalent4,7493,9063,52411,3679,8371,128
Short-term investments2,1103,1754,141   
Receivables   10666024
Inventory, net of allowances, customer advances and progress billings     2733
Inventory     2733
Prepaid expense    1 108
Deferred costs 261     
Other current assets99     
Other undisclosed current assets169316138479133
Total current assets:7,3887,1117,68111,57210,4021,427
Noncurrent Assets
Inventory, Noncurrent      33
Intangible asset, including goodwill, after accumulated amortization217241    
Intangible asset, excluding goodwill, after accumulated amortization217241    
Prepaid expense   657127 
Other noncurrent assets     61 
Other undisclosed noncurrent assets  59   (33)
Total noncurrent assets:217300657188 
TOTAL ASSETS:7,6057,4127,74611,64310,4901,427
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:5781,584703 418127
Accrued liabilities  60    
Other undisclosed accounts payable and accrued liabilities5781,524703 418127
Deferred revenue72727272  
Debt    364 15
Due to related parties✕✕✕✕ 72 
Total current liabilities:6501,656776436490142
Noncurrent Liabilities
Long-term debt and lease obligation      4
Long-term debt, excluding current maturities      4
Liabilities, other than long-term debt649722794866938 
Deferred revenue649722794866938 
Total noncurrent liabilities:6497227948669384
Total liabilities:1,3002,3781,5691,3021,428146
Equity
Equity, attributable to parent, including:6,3055,0346,17710,3419,0621,281
Common stock1000109
Treasury stock, value   (471)   
Additional paid in capital25,79120,29617,52617,51212,3157,035
Deferred compensation equity   (14)   
Accumulated other comprehensive income (loss)62(6)   
Accumulated deficit(19,492)(15,265)(10,872)(7,171)(3,263)(5,762)
Other undisclosed equity, attributable to parent   14   
Total equity:6,3055,0346,17710,3419,0621,281
TOTAL LIABILITIES AND EQUITY:7,6057,4127,74611,64310,4901,427

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues72727286 41
Other income    86 3
Cost of revenue(44)(6)(6)(6)(5)(176)
Cost of product and service sold      (176)
Other undisclosed gross profit    (14)71 
Gross profit:2866666666(135)
Operating expenses(4,308)(4,772)(3,922)(3,694)(2,811)(2,438)
Operating loss:(4,281)(4,706)(3,856)(3,628)(2,744)(2,573)
Nonoperating income (expense)53313225(280)6,926(465)
Investment income, nonoperating194333399(105)6,66012
Interest and debt expense(37)(5)(5)(2)19(198)
Income (loss) from continuing operations before equity method investments, income taxes:(4,265)(4,398)(3,636)(3,910)4,201(3,235)
Income (loss) from equity method investments    (105)6,660 
Other undisclosed income (loss) from continuing operations before income taxes3755107(6,680) 
Income (loss) from continuing operations before income taxes:(4,228)(4,393)(3,631)(3,907)4,182(3,235)
Income tax expense     (25) 
Income (loss) from continuing operations:(4,228)(4,393)(3,631)(3,907)4,157(3,235)
Income (loss) before gain (loss) on sale of properties:✕✕✕✕✕3,904(3,235)
Loss from discontinued operations   (70)(1)(253) 
Other undisclosed net income      198
Net income (loss):(4,228)(4,393)(3,701)(3,909)3,904(3,038)
Net loss attributable to noncontrolling interest    (3,909)(3,904) 
Other undisclosed net income attributable to parent    3,9093,904 
Net income (loss) attributable to parent:(4,228)(4,393)(3,701)(3,909)3,904(3,038)
Preferred stock dividends and other adjustments     (1,404)(69)
Other undisclosed net income available to common stockholders, basic     1,404 
Net income (loss) available to common stockholders, basic:(4,228)(4,393)(3,701)(3,909)3,904(3,107)
Other undisclosed net loss available to common stockholders, diluted     (1,404) 
Net income (loss) available to common stockholders, diluted:(4,228)(4,393)(3,701)(3,909)2,500(3,107)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income (loss):(4,228)(4,393)(3,701)(3,909)3,904(3,038)
Other comprehensive loss   (6)   
Comprehensive income (loss):(4,228)(4,393)(3,707)(3,909)3,904(3,038)
Comprehensive loss, net of tax, attributable to noncontrolling interest    (3,909)(3,904) 
Other undisclosed comprehensive income (loss), net of tax, attributable to parent39    
Comprehensive loss, net of tax, attributable to parent:(4,224)(4,384)(3,707)(7,817) (3,038)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: